@article{article, title  = {{2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guérin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/j.annonc.2023.09.2825 }},

 year = {{2023}},

 month = {{10}},

 author = {{Necchi A and Catto JWF and Powles TB and Guerrero-Ramos F and Simone G and Shore ND and Salinas J and Merseburger AS and Roumiguié M and Kitamura H and Morris D et al}},

 doi = {{10.1016/j.annonc.2023.09.2825}},

 volume = {{34}},

 journal = {{Annals of Oncology}},

 pages = {{S1224-S1224}},

 note = {{Accessed on 2024/12/22}}}